Cart

SCIENCE BEHIND ACUTESHIELD FORTRESS™

The Study of Virology (Influenza)

PATENT PENDING LIPOSOMAL FORMULA

RANKING OF NUTRACEUTICALS BY ANTI-INFLUENZA EFFICACY

Based on a comprehensive review of peer-reviewed studies, including meta-analyses, clinical trials, and preclinical data, the 20 nutraceuticals were ranked by their demonstrated efficacy against influenza viruses (Influenza A subtypes H5N1 (Bird Flu), H1N1, H3N2 (Super Flu 2026), H7N9, H9N2; Influenza B, C, and D). Efficacy was assessed by the strength and consistency of evidence: high (robust in vitro/in vivo inhibition of viral replication/entry, broad subtype coverage, and human/animal data showing reduced symptoms/viral load); medium (strong preclinical data with some human support or indirect effects via antioxidant/anti-inflammatory mechanisms); low (limited, subtype-specific, or indirect evidence, often secondary to general immune support). EGCG and NAC topped the list due to direct broad-spectrum antiviral mechanisms like hemagglutination inhibition and ROS modulation. Ingredients like Vitamin E and PQQ ranked lower due to sparse, indirect data.

RANKED #1 SEASONAL VIROLOGY FORMULA

ACUTESHIELD FORTRESS™ SUPPORTS 7 HEALTH AREAS

  • Inhibits Viral Entry/Replication *
  • Combats Cytokine Storm/Oxidative Damage *
  • Antiviral/Antioxidant Synergy *
  • Reduces Inflammation/Thrombosis *
  • Promotes Mitochondria Energy Functions *
  • Reduces Symptom Duration/Severity *
  • Specific Type A (H3N2 Super Flu – 2026) Relevance *

MaxAbsorb98™ | MaxStrength™ | PeakResults™ | Patent Pending

HIGH/MEDIUM RANKINGS PROMOTE & SUPPORT VIROLOGY (INFLUENZA) HEALTH

HIGH/MEDIUM/LOW RANKINGS PROMOTE & SUPPORT MULTIPLE SYNERGISTIC BENEFITS

MEDIUM/LOW VIROLOGY RANKINGS SUPPORT HIGH/MEDIUM MITOCHONDRIA FUNCTIONS

* These observations are from peer reviewed scientific research papers cited below

INFLUENZA NUTRACEUTICALS RANKED HIGHEST TO LOWEST IMPACT

Rank Nutraceutical Efficacy Level Key Rationale
1 Epigallocatechin-3-Gallate (EGCG) 100mg High Potent inhibition of viral attachment/replication across Influenza A/B subtypes via hemagglutination blockade and ROS scavenging; in vitro/in vivo data show reduced viral load and lung pathology.
2 N-acetylcysteine 500mg High Suppresses viral replication and cytokine storm in H1N1/H5N1 models; enhances glutathione to mitigate oxidative stress; clinical evidence for reduced symptoms in respiratory infections.
3 Quercetin (from Capparis Sinaica Veill extract) 250mg High Inhibits H1N1/H3N2 entry/replication via NA/HA interference; broad subtype coverage in preclinical studies; synergizes with zinc for antiviral effects.
4 IsoQuercetin (from Capparis Sinaica Veill extract) 250mg High Superior to quercetin in inhibiting H1N1/B viruses; reduces HA/M1 expression; in vivo mouse models show decreased lung titers.
5 Rutin (from Capparis Sinaica Veill extract) 250mg High Blocks H5N1 replication via PB2 inhibition; restores oxidative balance in infected tissues; effective across A subtypes in vitro.
6 Curcumin 250mg Medium Inhibits H5N1/H1N1 adsorption/replication via NF-κB/TLR pathways; reduces pneumonia in animal models; broad but variable subtype efficacy.
7 Resveratrol 200mg Medium Suppresses H1N1 replication and inflammation; enhances sirtuin-mediated antiviral responses; preclinical data for respiratory viruses.
8 L-Glutathione 250mg Medium Blocks H1N1 replication via redox maintenance; protects epithelial cells from oxidative damage; supports immune function in deficiency states.
9 Bromelain 250mg Medium Cleaves viral glycoproteins for H1N1 inhibition; mucolytic/anti-inflammatory effects reduce symptoms; limited subtype data.
10 Sulforaphane 200mg Medium Activates Nrf2/HO-1 to inhibit H1N1 replication; preclinical antiviral via ROS modulation; broad potential but sparse influenza-specific evidence.
11 Genistein 50mg Medium Inhibits arenavirus entry (analogous to influenza); kinase modulation reduces replication; indirect antiviral via immune enhancement.
12 Selenium 200mcg Low Enhances vaccine responses and GPx activity against H9N2; deficiency increases virulence; supportive but not direct antiviral.
13 Superoxide Dismutase 1 (SOD1) 250mg Low Reduces ROS in H1N1 models; protects lung epithelium; indirect via oxidative stress mitigation.
14 Extra Virgin Olive Oil (Hydroxytyrosol) 175mg Low Disrupts H1N1/H9N2 envelopes; antioxidant protection; limited broad efficacy data.
15 Vitamin E 4mg Low Mitigates oxidative damage in H3N2 infection; supports immune response; secondary antioxidant role.
16 Ubiquinol CoQ10 200mg Low Mitochondrial support reduces H1N1 oxidative stress; indirect via energy/antioxidant pathways.
17 Nicotinamide Adenine Dinucleotide 250mg Low Boosts NAD+ for antiviral immunity; preclinical data for respiratory viruses; limited influenza-specific.
18 Pyrroloquinoline Quinone 100mg Low Promotes mitochondrial biogenesis; potential ROS reduction; no direct anti-influenza evidence.
19 Nattokinase 100mg Low Fibrinolytic/anti-inflammatory; no specific influenza data; indirect via immune modulation.

Brief Paragraph Summaries and Supporting Studies

Curcumin 250mg: Curcumin, a polyphenol from turmeric, exhibits broad anti-influenza activity by inhibiting viral adsorption and replication through NF-κB suppression and TLR pathway modulation, reducing lung inflammation and oxidative stress in H5N1/H1N1 models. Preclinical studies demonstrate reduced viral titers and pneumonia severity, with potential for subtype-spanning protection via direct virucidal effects, though human data remain limited to supportive roles in respiratory infections.

Resveratrol 200mg: Resveratrol, a stilbenoid from grapes, inhibits influenza replication by activating sirtuins/AMPK pathways and reducing proinflammatory cytokines, showing efficacy against H1N1 and respiratory viruses in preclinical models. It enhances antiviral immunity and limits lung damage, with human trials indicating reduced symptom duration, positioning it as a supportive agent for broad viral prophylaxis.

L-Glutathione 250mg: L-Glutathione, a key cellular antioxidant, blocks influenza replication by maintaining redox balance and inhibiting viral entry in H1N1 models, with deficiency exacerbating pathology. Supplementation restores GSH levels, reduces oxidative stress, and enhances immune responses, supported by in vitro evidence of protection against enveloped viruses like influenza.

Vitamin E 4mg: Vitamin E, a lipid-soluble antioxidant, mitigates influenza-induced oxidative damage in H3N2 models by stabilizing membranes and reducing lipid peroxidation, with supplementation restoring lung antioxidant defenses. Preclinical data show dose-dependent protection against viral pathology, though human efficacy is indirect via general immune support.

Ubiquinol CoQ10 200mg: Ubiquinol CoQ10 supports mitochondrial function and reduces oxidative stress in influenza models, indirectly limiting viral replication via enhanced energy metabolism and antioxidant capacity. Limited preclinical evidence suggests protection against respiratory damage, with human data focused on general cardio-respiratory benefits rather than direct antiviral effects.

Selenium 200mcg: Selenium enhances GPx activity and immune responses, reducing H9N2/H5N1 virulence in deficient models and boosting vaccine efficacy. Preclinical studies show decreased viral shedding and inflammation, with human data supporting its role in preventing severe outcomes via antioxidant support.

N-acetylcysteine 500mg: N-acetylcysteine replenishes glutathione, inhibiting H5N1/H9N2 replication and cytokine storm via ROS neutralization and TLR4 blockade. In vitro/in vivo data confirm reduced lung injury and viral load, with clinical evidence for symptom alleviation in respiratory infections.

Bromelain 250mg: Bromelain cleaves viral glycoproteins, inhibiting H1N1 entry and replication while reducing mucus viscosity and inflammation. Preclinical studies show enhanced antiviral immunity and symptom relief, with potential for broad enveloped virus protection.

Quercetin (from Capparis Sinaica Veill extract) 250mg: Quercetin inhibits influenza entry/replication via NA/HA blockade and PB2 targeting, effective against H1N1/H3N2/H5N1. In vitro/in vivo data show reduced viral load and oxidative stress, with human trials supporting respiratory benefits.

IsoQuercetin (from Capparis Sinaica Veill extract) 250mg: Isoquercetin outperforms quercetin in inhibiting H1N1/B replication via HA/M1 suppression, with in vivo mouse models showing lung protection. Broad efficacy across subtypes via enhanced bioavailability.

Rutin (from Capparis Sinaica Veill extract) 250mg: Rutin blocks H5N1 replication via PB2 inhibition and restores redox balance in infected tissues. In vitro data confirm antiviral activity across A subtypes, with supportive antioxidant effects.

Superoxide Dismutase 1 (SOD1) 250mg: SOD1 reduces ROS in H1N1 models, protecting lung epithelium and limiting viral enhancement via oxidative stress. Preclinical evidence supports indirect antiviral role through redox maintenance.

Extra Virgin Olive Oil (Hydroxytyrosol) 175mg: Hydroxytyrosol disrupts H1N1/H9N2 envelopes and reduces oxidative damage. In vitro studies show virucidal effects on enveloped viruses, with supportive antioxidant benefits.

Nattokinase 100mg: Nattokinase exhibits fibrinolytic/anti-inflammatory effects, with indirect antiviral potential via immune modulation. Limited influenza data; supportive for respiratory health but no direct efficacy.

Nicotinamide Adenine Dinucleotide 250mg: NAD+ boosts antiviral immunity and reduces replication in respiratory models via metabolic support. Preclinical data suggest broad potential, but influenza-specific evidence is sparse.

Pyrroloquinoline Quinone 100mg: PQQ promotes mitochondrial biogenesis and ROS reduction, with potential indirect antiviral effects. No direct influenza studies; benefits limited to general antioxidant support.

FDA Disclaimer:
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. These products should not be taken by pregnant women or children under the age of 18 years. The Federal Food and Drug Act require this notice.

 

Back to AcuteShield Fortress™ Product